CONMED (NYSE:CNMD) Posts Earnings Results, Beats Estimates By $0.14 EPS

CONMED (NYSE:CNMD) released its quarterly earnings results on Wednesday. The company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.14, Zacks reports. CONMED had a return on equity of 13.84% and a net margin of 10.23%. CONMED updated its FY 2025 guidance to 4.250-4.400 EPS.

CONMED Stock Up 2.0 %

Shares of CONMED stock traded up $1.47 during trading hours on Wednesday, hitting $74.35. The company had a trading volume of 573,352 shares, compared to its average volume of 415,094. The company’s 50-day moving average is $70.62 and its two-hundred day moving average is $70.19. CONMED has a twelve month low of $61.05 and a twelve month high of $88.60. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.27 and a quick ratio of 1.06. The company has a market cap of $2.30 billion, a P/E ratio of 17.66, a price-to-earnings-growth ratio of 1.04 and a beta of 1.46.

CONMED Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 3rd. Shareholders of record on Friday, December 20th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Friday, December 20th. This represents a $0.80 dividend on an annualized basis and a yield of 1.08%. CONMED’s payout ratio is currently 19.00%.

Analysts Set New Price Targets

CNMD has been the topic of several analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $97.00 price objective on shares of CONMED in a research note on Thursday, October 31st. StockNews.com cut CONMED from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, CONMED presently has a consensus rating of “Moderate Buy” and an average target price of $79.80.

CONMED Company Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.